Chronic myeloid leukemia (CML) is a hematopoietic disorder, characterized by the rearrangement of the fusion oncogene BCR-ABL1 that encodes an oncoprotein with dysregulated ABL1 tyrosine kinase activity (1–3). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.